托伐普坦对慢性心力衰竭患者容量负荷及血清钠水平的影响

发布时间：2018-06-25 05:48

本文选题：慢性心力衰竭 + 托伐普坦　；参考：《山东医药》2017年20期

【摘要】：目的探讨托伐普坦对慢性心力衰竭(CHF)患者容量负荷及血清钠水平的影响。方法选取CHF患者94例,随机分为对照组和观察组各47例,两组均给予常规CHF治疗方案,观察组另外给予托伐普坦,两组疗程均为3个月。两组治疗前后检测心脏容量负荷指标,包括左室舒张末期压力(LVEDP)、心输出量(CO)、右心房压(RAP)、肺动脉嵌压(PAWP)、肺动脉压(PAP);治疗前及治疗后1、3个月检测血清钠水平。结果两组治疗前LVEDP、CO、RAP、PAWP、PAP比较差异均无统计学意义(P均0.05);治疗后两组LVEDP、RAP、PAWP、PAP均较治疗前降低,CO均较治疗前升高,且观察组上述变化更显著(P均0.05)。治疗前两组血清钠水平比较差异无统计学意义(P0.05);治疗1、3个月时,对照组血清钠水平较治疗前逐渐下降,观察组血清钠水平较治疗前逐渐升高,且观察组血清钠水平均高于对照组,组间及组内比较P均0.05。结论托伐普坦能有效降低CHF患者的容量负荷,并能预防低钠血症的发生。
[Abstract]:Objective to investigate the effect of torvalptan on volume load and serum sodium level in patients with chronic heart failure (CHF). Methods Ninety-four patients with CHF were randomly divided into two groups: the control group (n = 47) and the observation group (n = 47). Left ventricular end-diastolic pressure (LVEDP), cardiac output (CO), right atrial pressure (rap), pulmonary artery pressure (PAWP), pulmonary artery pressure (PAP), and serum sodium levels were measured before and after treatment. Results there was no significant difference between the two groups before and after treatment (P 0.05), and after treatment, the decrease of CO in the two groups was higher than that before treatment, and the above changes in the observation group were more significant (P 0.05). There was no significant difference in serum sodium levels between the two groups before treatment (P0.05); after 1 and 3 months of treatment, the serum sodium levels in the control group decreased gradually compared with those before treatment, and the serum sodium levels in the observation group gradually increased compared with those before treatment. The serum sodium level in the observation group was higher than that in the control group (P < 0.05). Conclusion Tofaptan can effectively reduce the volume load and prevent hyponatremia in CHF patients.
【作者单位】：河北大学附属医院;
【分类号】：R541.6

【相似文献】